Personalized Medicine in Brief: Vol. 9 (Fall 2017)

In addition to descriptions of the most important developments in the field, PMC's newsletter, Personalized Medicine in Brief, provides analyses of personalized medicine's most pressing issues and outlines the Coalition's efforts to address them. The Fall 2017 edition analyzes, among other developments, the significance of several new FDA approvals; a new agreement between Amgen and Harvard Pilgrim Health Care in which the companies share the risk of prescribing a personalized medicine that promises to deliver value in part by delivering downstream benefits; ongoing concerns over the price of personalized medicines; and efforts by medical centers to integrate personalized medicine in clinical settings.

Previous Newsletter Issues

Join Today

PMC members shape and advance the future of personalized medicine.
Join Today